Mounjaro Eligibility UK: Clinical Criteria and How to Qualify in 2026

A comprehensive clinician-led guide to the latest UK eligibility requirements, BMI thresholds, and safety protocols for Mounjaro weight loss treatment.

Table of Contents

• Your Clinical Partner: The Slinic Approach
• Understanding Mounjaro Eligibility in the UK: The Regulatory Framework
• The Core Clinical Criteria: BMI and Weight-Related Health Conditions
• Clinical Contraindications: Who Should Not Use Mounjaro?
• The Slinic Approach: Our Robust Eligibility Assessment Process
• Starting Your Journey: Cost, Expectations, and Long-Term Success
• Frequently Asked Questions

Your Clinical Partner: The Slinic Approach

Slinic is a UK-based, GPhC-registered online pharmacy (No. 1033729) specialising in clinically supervised medical weight loss. Our team of registered Pharmacists and Prescribing Doctors, operating from our physical pharmacy in North West England, provides evidence-based weight loss treatments with a steadfast commitment to patient safety and high professional accountability.

Our ‘safety-first’ approach is built on robust clinical governance, ensuring every patient undergoes a comprehensive eligibility assessment before a prescription is issued. We believe that eligibility is more than a static BMI number; it is a dynamic clinical safety framework designed to ensure Mounjaro acts as a sustainable medical foundation for your long-term health. This guide outlines the precise criteria we use to determine if this weight loss treatment is appropriate and safe for you.

Understanding Mounjaro Eligibility in the UK: The Regulatory Framework

Before assessing your individual eligibility, it is essential to understand the clinical and regulatory landscape for Mounjaro in the UK.

• What is Mounjaro? Mounjaro is the UK brand name for Tirzepatide, a dual-action GIP and GLP-1 receptor agonist licensed for weight management. It works by regulating appetite and blood sugar, making it a powerful tool within a comprehensive medical weight loss programme.
• NICE and MHRA Approval: The National Institute for Health and Care Excellence (NICE) provides guidance on its use, while the Medicines and Healthcare products Regulatory Agency (MHRA) approves its license for weight loss treatment in the United Kingdom. Our protocols for 2026 are fully aligned with these national standards.
• NHS vs. Private Criteria: Eligibility criteria for NHS services and private clinics like Slinic are based on the same clinical safety principles. However, private services can offer faster access to assessment and treatment without the need for a GP referral or long waiting lists.

NICE Guidelines and the UK Licensing Standards

NICE guidance (TA1026) outlines the use of Tirzepatide for managing overweight and obesity. It specifies that the treatment should be prescribed as part of a multidisciplinary, weight-management strategy that includes a reduced-calorie diet and increased physical activity. While the active ingredient is the same as the US-branded Zepbound, Mounjaro is the sole brand name licensed and available for this purpose in the UK.

Private vs. NHS Access: Why Criteria Might Differ

While both sectors adhere to strict clinical governance, the primary difference lies in access and delivery. Private clinics like Slinic provide a direct, efficient pathway to assessment and treatment, managed by our team of GPhC-regulated clinicians. We ensure the same high standards of professional accountability and patient safety as the NHS, but with the added convenience of online consultations and discreet home delivery. For those exploring public sector routes, you can learn more about NHS weight loss injections 2026 eligibility.

The Core Clinical Criteria: BMI and Weight-Related Health Conditions

Our clinical assessment for Mounjaro is centred on established medical guidelines to ensure patient safety and treatment efficacy. The primary eligibility criteria are based on your Body Mass Index (BMI).

• Primary Threshold: A BMI of 30kg/m² or greater, which is classified as obesity.
• Secondary Threshold: A BMI between 27kg/m² and 30kg/m² (classified as overweight) accompanied by at least one weight-related health condition (comorbidity).

While BMI is a crucial baseline metric, it is not the sole factor in our comprehensive medical weight loss assessment. We require accurate height and weight measurements to begin our clinical review, which considers your full health profile.

Recognised Weight-Related Comorbidities

For individuals with a BMI between 27 and 30, eligibility for Mounjaro requires the presence of a clinically recognised weight-related comorbidity. These conditions are often worsened by excess weight, and weight loss can lead to significant health improvements. They include:

• Type 2 diabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or other abnormal fat levels in the blood)
• Obstructive sleep apnoea
• Cardiovascular disease (e.g., history of heart attack or stroke)

During our confidential online pharmacy consultation, we will ask you to disclose any such conditions, which are then carefully reviewed by our clinical team.

Adjusted BMI Thresholds for Specific Ethnic Groups

In line with NICE recommendations, we apply lower BMI thresholds for individuals of South Asian, Chinese, or Black African descent. This clinical adjustment, typically a reduction of 2.5 points (e.g., a threshold of 27.5kg/m² instead of 30), is due to evidence showing a higher risk of conditions like type 2 diabetes at a lower BMI in these populations. This reflects the different biological architecture of fat distribution and is a core part of Slinic’s commitment to inclusive, evidence-based healthcare.

Clinical Contraindications: Who Should Not Use Mounjaro?

Our ‘safety-first’ approach means we must identify patients for whom Mounjaro is not a suitable or safe treatment. There are several absolute contraindications where we cannot prescribe this medication.

• Pregnancy and Breastfeeding: Mounjaro is strictly contraindicated if you are pregnant, breastfeeding, or planning to conceive.
• Thyroid Cancer History: A personal or family history of Medullary Thyroid Carcinoma (MTC) is an absolute contraindication.
• MEN 2 Syndrome: Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) must not use Mounjaro.
• Contraception Interaction: Mounjaro can reduce the absorption of oral contraceptives. We advise female patients to use an additional barrier method, like condoms, for the first 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.

Gastrointestinal and Pancreatic Considerations

A thorough review of your medical history is vital to prevent complications. We may not be able to prescribe Mounjaro if you have:

• A history of severe or acute pancreatitis.
• Active gallbladder disease.
• Severe gastrointestinal disease, particularly gastroparesis (delayed gastric emptying), as Mounjaro can exacerbate this condition.

Our structured follow-ups are designed to manage potential Mounjaro side effects and ensure your ongoing safety.

Medication Interactions and Polypharmacy

Patient safety requires full transparency about your current medications. It is critical to disclose everything you are taking during your clinical assessment.

• Other GLP-1s: Mounjaro must not be combined with other GLP-1 agonists, such as Wegovy (semaglutide) or Saxenda (liraglutide).
• Diabetes Medications: If you take insulin or sulphonylureas, using Mounjaro can increase the risk of hypoglycemia (low blood sugar). Your treatment plan may need careful adjustment and monitoring.

The Slinic Approach: Our Robust Eligibility Assessment Process

To ensure Mounjaro is prescribed safely and appropriately, Slinic has developed a multi-stage, audit-ready assessment process managed entirely by our clinical team.

• Step 1: Digital Clinical Consultation: You begin by completing a comprehensive health questionnaire. This secure form gathers the necessary information about your medical history, current health status, and treatment goals.
• Step 2: Expert Clinical Review: Your submission is meticulously reviewed by our UK-registered Pharmacists and Prescribing Doctors. They assess your information against the strict clinical criteria for Mounjaro.
• Step 3: Verification and Safety Checks: We conduct identity verification and cross-reference your health data to confirm eligibility. In complex cases, we may request a video consultation to ensure absolute clarity and patient safety.
• Step 4: Clinical Decision and Treatment Plan: If you are deemed eligible, our prescribers will issue a prescription and generate a bespoke treatment plan, including dosage titration guidance and safety information.

Expert-Led Clinical Governance

Our ‘safety-first’ philosophy is at the core of our operations. We only prescribe Mounjaro when it is clinically appropriate and safe to do so. Our North West England-based pharmacy ensures high professional accountability, with documented protocols and clear escalation pathways for any clinical concerns.

Discreet Delivery and Ongoing Monitoring

Once your eligibility is confirmed, your Mounjaro weight loss injections are dispatched via fast, discreet nationwide delivery. Our duty of care does not end there. We provide a structured follow-up process to support you through dosage titration, offer advice on managing side effects, and monitor your progress, ensuring you feel supported throughout your medical weight loss journey.

To begin your assessment, please visit the Mounjaro weight loss UK shop.

Starting Your Journey: Cost, Expectations, and Long-Term Success

Mounjaro is a powerful medical tool, but it is most effective when integrated into a healthier lifestyle. A calorie-controlled diet and increased physical activity are essential for achieving and maintaining long-term success.

Clinical trials (SURMOUNT programme) have demonstrated that patients using Tirzepatide can achieve significant weight loss, with some studies showing an average reduction of up to 22.5% of body weight over 72 weeks. The Slinic experience is designed to merge this clinical success with an improved quality of life, helping you build a restorative foundation for lasting health.

Mounjaro Pricing and Value in the UK

We are committed to transparent and competitive UK pricing with no hidden fees. The cost of your Mounjaro treatment includes the comprehensive clinical review by our prescribers, the private prescription, the medication itself, and our ongoing clinical support. For a detailed overview, please see our complete Mounjaro cost breakdown for 2026.

Building a Restorative Foundation for Health

This weight loss treatment should be viewed as a catalyst for profound, long-term biological health improvements. By combining Mounjaro with sustainable lifestyle changes, you can achieve meaningful results that extend far beyond the number on the scale. For guidance on nutritional integration, we encourage you to read our Mounjaro diet guide.

If you are ready to take the next step and see if you qualify, our clinical team is here to support you.

Begin your clinical assessment for Mounjaro with Slinic today

Frequently Asked Questions

What is the minimum BMI for Mounjaro in the UK?
The minimum BMI is 30kg/m², or 27kg/m² if you have at least one qualifying weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol.

Can I get Mounjaro if I am not diabetic?
Yes. Mounjaro is licensed in the UK for weight management in individuals with obesity (BMI ≥30) or who are overweight (BMI ≥27) with a comorbidity, regardless of whether they have type 2 diabetes.

Is Mounjaro available on the NHS for weight loss?
Mounjaro is approved by NICE for use within specialist NHS weight management services, but access can be limited by long waiting lists and strict local commissioning criteria. Private clinics like Slinic offer a faster, more direct route to access treatment if you meet the clinical criteria.

What health conditions make me ineligible for Mounjaro?
Absolute contraindications include a personal or family history of Medullary Thyroid Carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy, or breastfeeding. A history of pancreatitis or severe gastrointestinal disease like gastroparesis may also make you ineligible.

Do I need a GP referral to buy Mounjaro from Slinic?
No, a GP referral is not required. Our GPhC-registered prescribers will conduct a full clinical assessment based on the detailed health questionnaire you complete to determine if Mounjaro is safe and appropriate for you.

Can I switch from Wegovy to Mounjaro if I meet the criteria?
Yes, it is possible to switch from Wegovy (semaglutide) to Mounjaro. This must be done under clinical supervision to ensure a safe transition and appropriate washout period. You will need to complete our online consultation for a clinician to assess your suitability for the switch.

How does the Slinic clinical assessment work?
Our process begins with a comprehensive online health questionnaire. This is reviewed by our registered pharmacists and prescribers, who verify your identity and medical history. If you meet all the safety and clinical criteria, a prescription is issued and your treatment is dispatched.

Is Mounjaro safe for long-term weight management?
Mounjaro has been approved for long-term use in managing weight based on extensive clinical trials. Our ongoing monitoring and structured follow-ups are in place to ensure your continued safety and to manage any side effects throughout your treatment journey.

• Author: Slinic Clinical Pharmacy Team
• Medical Reviewer: Shadeia Younis Pharmacist Lead
• Reviewed:Mach 2026

Safety Notice: This information is for educational purposes and doesn’t replace professional medical advice. Weight loss injections are prescription-only medicines and require a consultation with a registered healthcare professional. If you experience severe side effects like intense abdominal pain, breathing difficulties, or swelling, contact emergency services immediately. Always read the patient information leaflet before starting any weight loss treatment.